Wu Z, Zhao J, Lam W, et al. - Researchers conducted this multicentral prospective, randomised controlled trial to compare the recurrence rate and surgical complications of retinopathy of prematurity (ROP) between patients treated with intravitreal injection of conbercept (IVC) and intravitreal injection of ranibizumab (IVR) within 6 months. In total, 30 infant patients (60 eyes) underwent IVC and 30 patients (60 eyes) underwent IVR. In total, 10 eyes (16.67%) in the IVC group and 14 eyes (23.34%) in the IVR group developed recurrence. For the treatment of ROP, both IVC and IVR are effective therapies. Conbercept is a new treatment choice for ROP.